HK99687A - Process for the manufacture of highly crystalline sodium cefoperazone - Google Patents

Process for the manufacture of highly crystalline sodium cefoperazone Download PDF

Info

Publication number
HK99687A
HK99687A HK996/87A HK99687A HK99687A HK 99687 A HK99687 A HK 99687A HK 996/87 A HK996/87 A HK 996/87A HK 99687 A HK99687 A HK 99687A HK 99687 A HK99687 A HK 99687A
Authority
HK
Hong Kong
Prior art keywords
acetone
cefoperazone
water
sodium
sodium cefoperazone
Prior art date
Application number
HK996/87A
Other languages
German (de)
English (en)
Inventor
Daniel Joseph O'brien
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HK99687A publication Critical patent/HK99687A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36—Methylene radicals, substituted by sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (3)

1. Procédé de préparation de céfopérazone sodique cristalline substantiellement dépourvue de matériaux amorphes, qui consiste (a) à combiner une solution eau/acétone/céfopérazone sodique contenant 1-1,5 partie d'eau en volume, 2,0-5,0 parties d'acétone en volume, et 1 partie de céfopérazone sodique en poids avec suffisamment d'acétone pour donner une solution eau/ acétone contenant d'environ 14% à environ 17% (v/v) d'eau par rapport à la concentration en acétone à une température d'environ 5-25°C; (b) à ajouter suffisamment d'acétone à la solution résultante à ladite température pour donner une solution eau/acétone contenant environ 3% à 5% d'eau par rapport à la concentration d'acétone; et (c) à séparer la céfopérazone sodique cristalline résultante de ladite bouillie.
2. Procédé selon la revendication 1, dans lequel ladite température est de 18-25°C.
3. Procédé selon la revendication 1, caractérisé en ce que ladite solution eau/acétone/céfopérazone sodique est formée in-situé en combinant une bouillie de céfopérazone dépourvue d'acide dans de l'acétone avec une solution aqueuse contenant environ en équivalent d'une base choisie dans le groupe comprenant le bicarbonate de sodium, le carbonate de sodium et le 2-éthylhexanoate de sodium.
HK996/87A 1983-02-07 1987-12-24 Process for the manufacture of highly crystalline sodium cefoperazone HK99687A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/464,223 US4456753A (en) 1983-02-07 1983-02-07 Process for the manufacture of highly crystalline sodium cefoperazone

Publications (1)

Publication Number Publication Date
HK99687A true HK99687A (en) 1987-12-31

Family

ID=23843028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK996/87A HK99687A (en) 1983-02-07 1987-12-24 Process for the manufacture of highly crystalline sodium cefoperazone

Country Status (22)

Country Link
US (1) US4456753A (fr)
EP (1) EP0118196B1 (fr)
JP (1) JPH0643429B2 (fr)
KR (1) KR870001071B1 (fr)
AU (1) AU541675B2 (fr)
CA (1) CA1190220A (fr)
DE (1) DE3461802D1 (fr)
DK (1) DK152757C (fr)
ES (1) ES529485A0 (fr)
FI (1) FI75571C (fr)
GR (1) GR81694B (fr)
HK (1) HK99687A (fr)
HU (1) HU190544B (fr)
IE (1) IE56752B1 (fr)
IL (1) IL70872A (fr)
NZ (1) NZ207038A (fr)
PH (1) PH19052A (fr)
PL (1) PL146540B1 (fr)
PT (1) PT78058B (fr)
SG (1) SG70087G (fr)
YU (1) YU43562B (fr)
ZA (1) ZA84853B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1148049T1 (en) 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1999024441A1 (fr) * 1997-11-10 1999-05-20 Dsm N.V. Cristallisation de composes de beta-lactame
US6979735B1 (en) * 1999-04-01 2005-12-27 Dsm N.V. Agglomerates by crystallization
IT1318467B1 (it) * 2000-04-14 2003-08-25 Antibioticos Spa Processo per la sintesi di cefoperazone sodico ad elevatacristallinita'.
WO2007035911A1 (fr) * 2005-09-21 2007-03-29 Novabay Pharmaceuticals, Inc. Systeme et procede pour la prevention et le traitement d'infections d'origine bacterienne et fongique comprenant des infections de la voie urinaire mettant en oeuvre des compositions a base d'acide hypohaleux
CN101863907B (zh) * 2010-07-07 2012-05-23 福建省福抗药业股份有限公司 一种头孢哌酮钠的结晶方法
CN104470933A (zh) * 2012-07-17 2015-03-25 中化帝斯曼制药有限公司荷兰公司 头孢哌酮钠新晶型
CN103951679B (zh) * 2014-04-29 2016-04-27 悦康药业集团有限公司 一种头孢哌酮钠化合物及其药物组合物
CN104327099A (zh) * 2014-09-29 2015-02-04 联合康兴（北京）医药科技有限公司 头孢哌酮钠化合物实体及组合物和用途
CN105440057B (zh) * 2015-11-25 2017-10-17 华北制药河北华民药业有限责任公司 一种制备头孢哌酮钠的方法
CN112442048B (zh) * 2020-11-10 2022-04-08 华北制药河北华民药业有限责任公司 一种头孢匹胺钠的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087424A (en) * 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
GB1508071A (en) * 1976-01-19 1978-04-19 Toyama Chemical Co Ltd Cephalosporins and process for producing the same
DE2600880C2 (de) * 1976-01-12 1984-09-13 Toyama Chemical Co. Ltd., Tokio / Tokyo Cephalosporinverbindungen
IL53427A0 (en) * 1976-11-24 1978-01-31 Lilly Co Eli Method of preparing a rapidly dissolving powder of sterile crystalline cefozolin sodium for parenteral administration

Also Published As

Publication number Publication date
EP0118196A1 (fr) 1984-09-12
ZA84853B (en) 1985-09-25
YU20684A (en) 1986-06-30
FI75571C (fi) 1988-07-11
CA1190220A (fr) 1985-07-09
FI840475A7 (fi) 1984-08-08
JPS59148789A (ja) 1984-08-25
GR81694B (fr) 1984-12-12
SG70087G (en) 1988-02-19
PL246090A1 (en) 1985-02-13
US4456753A (en) 1984-06-26
DE3461802D1 (en) 1987-02-05
NZ207038A (en) 1986-05-09
PT78058B (en) 1986-06-02
AU541675B2 (en) 1985-01-17
DK51784A (da) 1984-08-08
HU190544B (en) 1986-09-29
JPH0643429B2 (ja) 1994-06-08
IE840273L (en) 1984-08-07
DK51784D0 (da) 1984-02-06
IL70872A (en) 1987-08-31
IL70872A0 (en) 1984-05-31
PT78058A (en) 1984-03-01
FI840475A0 (fi) 1984-02-06
IE56752B1 (en) 1991-12-04
KR870001071B1 (ko) 1987-05-27
KR840007730A (ko) 1984-12-10
AU2420984A (en) 1984-08-16
YU43562B (en) 1989-08-31
HUT34208A (en) 1985-02-28
DK152757B (da) 1988-05-09
PH19052A (en) 1985-12-11
ES8504700A1 (es) 1985-05-01
ES529485A0 (es) 1985-05-01
FI75571B (fi) 1988-03-31
DK152757C (da) 1988-09-26
EP0118196B1 (fr) 1986-12-30
PL146540B1 (en) 1989-02-28

Similar Documents

Publication Publication Date Title
HU212583B (en) New process for producing potassium salt of clavulanic acid
EP0118196B1 (fr) Procédé pour la préparation de céfopérazone de sodium hautement cristallin
EP0112550B1 (fr) Sels d'addition d'acides cristallins de céphalosporines et procédé pour leur préparation
KR100200242B1 (ko) 클라불란산염의 제조 방법
JPH0641143A (ja) クラブラン酸塩の製造方法
US5726170A (en) Clavulanic acid salts
US4277601A (en) Preparation of sodium cefuroxime
US4219641A (en) Process for preparing erythromycin succinate
EP0101170B1 (fr) Procédé pour la préparation de céfopérazone de sodium
US2875247A (en) Refining of tetracycline antibiotics by direct mash extraction
US3905959A (en) Process for the manufacture of crystalline anhydrous ampicillin
EP0007689B1 (fr) Préparation de dérivés sodiques de céphamandole
KR0169534B1 (ko) 고밀도의 고결정성 세포페라존 나트륨염 및 그의 제조방법
KR100423890B1 (ko) 세팔로스포린 유도체의 새로운 제조방법
US3676427A (en) Process for the manufacture of the disodium salt of alpha-carboxybenzylpenicillin
US3502655A (en) Penicillins and process for preparing them
JPH0665254A (ja) セフォラニド誘導体
GB2144423A (en) 1-Methyl-5-nitro-imidazole derivatives
KR19980702445A (ko) 클라불란 산 염류

Legal Events

Date Code Title Description
PE Patent expired